BioCryst Pharmaceuticals (BCRX) Competitors $7.30 +0.09 (+1.25%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends BCRX vs. NK, TSHA, ADAP, VXRT, ALGS, HALO, IONS, ALKS, FOLD, and GERNShould you be buying BioCryst Pharmaceuticals stock or one of its competitors? The main competitors of BioCryst Pharmaceuticals include NantKwest (NK), Taysha Gene Therapies (TSHA), Adaptimmune Therapeutics (ADAP), Vaxart (VXRT), Aligos Therapeutics (ALGS), Halozyme Therapeutics (HALO), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Amicus Therapeutics (FOLD), and Geron (GERN). These companies are all part of the "medical" sector. BioCryst Pharmaceuticals vs. NantKwest Taysha Gene Therapies Adaptimmune Therapeutics Vaxart Aligos Therapeutics Halozyme Therapeutics Ionis Pharmaceuticals Alkermes Amicus Therapeutics Geron BioCryst Pharmaceuticals (NASDAQ:BCRX) and NantKwest (NASDAQ:NK) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, community ranking, institutional ownership, profitability and media sentiment. Does the MarketBeat Community favor BCRX or NK? BioCryst Pharmaceuticals received 210 more outperform votes than NantKwest when rated by MarketBeat users. Likewise, 66.53% of users gave BioCryst Pharmaceuticals an outperform vote while only 51.12% of users gave NantKwest an outperform vote. CompanyUnderperformOutperformBioCryst PharmaceuticalsOutperform Votes48366.53% Underperform Votes24333.47% NantKwestOutperform Votes27351.12% Underperform Votes26148.88% Which has higher valuation & earnings, BCRX or NK? NantKwest has lower revenue, but higher earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than NantKwest, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioCryst Pharmaceuticals$331.41M4.56-$226.54M-$0.61-11.97NantKwest$40K13,326.42-$65.79M-$0.70-6.96 Do insiders and institutionals hold more shares of BCRX or NK? 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 9.4% of NantKwest shares are held by institutional investors. 4.8% of BioCryst Pharmaceuticals shares are held by company insiders. Comparatively, 71.7% of NantKwest shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is BCRX or NK more profitable? BioCryst Pharmaceuticals has a net margin of -30.01% compared to NantKwest's net margin of -76,658.58%. BioCryst Pharmaceuticals' return on equity of 0.00% beat NantKwest's return on equity.Company Net Margins Return on Equity Return on Assets BioCryst Pharmaceuticals-30.01% N/A -24.06% NantKwest -76,658.58%-56.06%-46.93% Which has more volatility and risk, BCRX or NK? BioCryst Pharmaceuticals has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500. Comparatively, NantKwest has a beta of 2.61, meaning that its share price is 161% more volatile than the S&P 500. Does the media favor BCRX or NK? In the previous week, BioCryst Pharmaceuticals had 6 more articles in the media than NantKwest. MarketBeat recorded 6 mentions for BioCryst Pharmaceuticals and 0 mentions for NantKwest. BioCryst Pharmaceuticals' average media sentiment score of 0.91 beat NantKwest's score of 0.00 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment BioCryst Pharmaceuticals Positive NantKwest Neutral Do analysts prefer BCRX or NK? BioCryst Pharmaceuticals presently has a consensus target price of $15.60, suggesting a potential upside of 113.70%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe BioCryst Pharmaceuticals is more favorable than NantKwest.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCryst Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80NantKwest 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryBioCryst Pharmaceuticals beats NantKwest on 13 of the 18 factors compared between the two stocks. Ad WealthPressBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCRX vs. The Competition Export to ExcelMetricBioCryst PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.51B$2.95B$5.06B$8.89BDividend YieldN/A1.90%4.97%4.06%P/E Ratio-11.9717.8689.0213.30Price / Sales4.56222.321,207.2881.01Price / CashN/A160.0839.1736.03Price / Book-3.294.906.085.74Net Income-$226.54M-$41.63M$119.07M$225.93M7 Day Performance-2.01%-4.73%-1.84%-1.32%1 Month Performance-2.93%-6.53%-3.65%0.60%1 Year Performance43.14%25.63%31.62%26.23% BioCryst Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCRXBioCryst Pharmaceuticals4.2315 of 5 stars$7.30+1.2%$15.60+113.7%+35.2%$1.51B$331.41M-11.97530Short Interest ↓NKNantKwestN/A$4.88-8.8%N/A+20.4%$533.06M$40,000.00-6.41160Analyst ForecastHigh Trading VolumeTSHATaysha Gene Therapies3.9247 of 5 stars$2.01-5.2%$6.63+229.6%+11.7%$434.48M$15.45M3.19180ADAPAdaptimmune Therapeutics2.1006 of 5 stars$0.66-1.5%$3.16+375.8%+54.9%$170.08M$60.28M-3.02449Analyst RevisionHigh Trading VolumeVXRTVaxart2.1372 of 5 stars$0.61-1.6%$3.00+393.6%-22.1%$110M$7.38M-1.48109Analyst RevisionNews CoverageALGSAligos Therapeutics4.3215 of 5 stars$18.20-1.6%$75.00+312.1%+5.5%$65.30M$6.00M-1.3990High Trading VolumeHALOHalozyme Therapeutics4.9806 of 5 stars$45.76+2.1%$61.11+33.5%+14.4%$5.70B$829.25M15.15390Analyst ForecastIONSIonis Pharmaceuticals4.2197 of 5 stars$35.40+4.9%$60.65+71.3%-28.7%$5.33B$788M0.00800ALKSAlkermes4.7788 of 5 stars$27.91+1.6%$35.42+26.9%+15.4%$4.45B$1.51B14.312,100Positive NewsFOLDAmicus Therapeutics4.6577 of 5 stars$9.59+0.7%$17.63+83.8%-13.1%$2.84B$399.36M0.00480GERNGeron3.492 of 5 stars$3.99+5.3%$7.05+76.7%+98.5%$2.29B$240,000.000.00141 Related Companies and Tools Related Companies NK Competitors TSHA Competitors ADAP Competitors VXRT Competitors ALGS Competitors HALO Competitors IONS Competitors ALKS Competitors FOLD Competitors GERN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BCRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
